Bristol-Myers Squibb Company (BMY) Income Statement
BMY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBMY revenue and net income
Where BMY's revenue goes
2025Each bar shows an amount and its share of revenue. BMY kept 14.6% of revenue as net income.
BMY profit margins
BMY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −0.2% | +1.4% | +2.5% | +11.3% |
| Gross profit | −0.2% | −1.7% | +9.6% | +10.3% |
| Operating income | +133.1% | +14.7% | +25.0% | +13.3% |
| Net income | — | +3.7% | — | +16.2% |
| EPS (diluted) | +439.5% | −7.2% | −0.9% | +11.8% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BMY quarterly EPS vs estimates
Bristol Myers Squibb beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: October 29, 2026 (estimate $1.28).
BMY income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.20B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B |
| Cost of revenue | $13.94B | $13.97B | $10.69B | $10.14B | $19.62B | $20.82B | $8.89B | $6.49B | $5.82B | $4.93B |
| Gross profit | $34.26B | $34.33B | $34.31B | $36.02B | $26.76B | $21.70B | $17.25B | $16.07B | $14.96B | $14.49B |
| Research & development | $9.95B | $11.16B | $9.30B | $9.51B | $9.53B | $9.56B | $5.95B | $5.13B | $4.97B | $4.41B |
| Sales, general & admin | $7.24B | $7.87B | $7.68B | $15.63B | $7.69B | $7.66B | $4.87B | $4.55B | $4.85B | $5.00B |
| Total operating expenses | $20.54B | $28.45B | $26.12B | $26.92B | $17.22B | $17.21B | $10.81B | $9.68B | $9.72B | $9.32B |
| Operating income | $13.72B | $5.89B | $8.20B | $9.10B | $9.54B | $4.49B | $6.44B | $6.39B | $5.24B | $5.18B |
| Interest income | $1.02B | $1.45B | $877.0M | $1.86B | $550.0M | $71.0M | $69.0M | $380.0M | $33.0M | $15.0M |
| Interest expense | $1.89B | $1.95B | $1.17B | $1.23B | $1.33B | $1.42B | $656.0M | $183.0M | $196.0M | $167.0M |
| Income before taxes | $9.33B | −$8.38B | $8.44B | $7.71B | $8.10B | −$6.87B | $4.97B | $5.97B | $5.13B | $5.92B |
| Income taxes | $2.27B | $554.0M | $400.0M | $1.37B | $1.08B | $2.12B | $1.51B | $1.02B | $4.16B | $1.41B |
| Net income | $7.05B | −$8.95B | $8.03B | $6.33B | $6.99B | −$8.99B | $3.44B | $4.92B | $1.01B | $4.46B |
| EBITDA | $15.23B | $3.17B | $19.37B | $19.22B | $20.12B | $4.93B | $7.38B | $6.79B | $6.12B | $6.46B |
| EPS (diluted) | $6.15 | $1.14 | $7.39 | $7.70 | $7.50 | $6.44 | $4.67 | $3.98 | $3.01 | $2.83 |
| Gross margin | 71.1% | 71.1% | 76.2% | 78.0% | 57.7% | 51.0% | 66.0% | 71.3% | 72.0% | 74.6% |
| Operating margin | 28.5% | 12.2% | 18.2% | 19.7% | 20.6% | 10.6% | 24.6% | 28.3% | 25.2% | 26.7% |
| Net margin | 14.6% | −18.5% | 17.8% | 13.7% | 15.1% | −21.2% | 13.2% | 21.8% | 4.8% | 22.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B | $10.97B |
| Cost of revenue | $3.73B | $3.42B | $4.10B | $3.44B | $3.37B | $3.03B | $4.92B | $5.28B | $5.40B | $5.28B | $4.99B | $4.75B |
| Gross profit | $9.25B | $8.07B | $8.41B | $8.79B | $8.90B | $8.17B | $7.42B | $6.62B | $6.80B | $6.59B | $6.49B | $6.22B |
| Research & development | $2.96B | $2.65B | $2.59B | $2.53B | $2.58B | $2.26B | $2.79B | $2.35B | $2.29B | $2.69B | $2.48B | $2.18B |
| Sales, general & admin | $1.83B | $1.62B | $2.18B | $1.79B | $1.71B | $1.58B | $1.85B | $1.98B | $1.93B | $2.37B | $2.06B | $1.94B |
| Total operating expenses | $5.22B | $4.70B | $5.59B | $5.15B | $5.12B | $4.67B | $4.89B | $4.33B | $4.22B | $5.05B | $4.54B | $4.12B |
| Operating income | $4.03B | $3.37B | $2.81B | $3.64B | $3.77B | $3.50B | $2.53B | $2.29B | $2.58B | $1.53B | $1.95B | $2.10B |
| Interest income | — | — | $94.0M | $129.0M | $368.0M | $434.0M | $587.0M | $399.0M | — | — | — | $173.0M |
| Interest expense | $407.0M | $411.0M | $432.0M | $480.0M | $485.0M | $494.0M | $496.0M | $505.0M | $521.0M | $425.0M | $316.0M | $280.0M |
| Income before taxes | $4.09B | $3.24B | $1.47B | $3.11B | $1.77B | $2.97B | $175.0M | $1.68B | $1.29B | −$11.52B | $1.67B | $2.14B |
| Income taxes | $770.0M | $561.0M | $384.0M | $919.0M | $460.0M | $509.0M | $99.0M | $461.0M | −$398.0M | $392.0M | −$88.0M | $203.0M |
| Net income | $3.32B | $2.68B | $1.09B | $2.20B | $1.31B | $2.46B | $72.0M | $1.21B | $1.68B | −$11.91B | $1.76B | $1.93B |
| EBITDA | $5.09B | $4.25B | $2.88B | $4.61B | $3.27B | $4.48B | $2.55B | $4.77B | $4.40B | −$8.56B | $4.45B | $4.85B |
| EPS (diluted) | $2.04 | $1.58 | $1.26 | $1.63 | $1.46 | $1.80 | $1.67 | $1.80 | $2.07 | −$4.40 | $1.59 | $2.00 |
| Gross margin | 71.3% | 70.2% | 67.2% | 71.9% | 72.5% | 72.9% | 60.2% | 55.6% | 55.7% | 55.5% | 56.6% | 56.7% |
| Operating margin | 31.0% | 29.3% | 22.5% | 29.8% | 30.8% | 31.2% | 20.5% | 19.2% | 21.2% | 12.9% | 17.0% | 19.2% |
| Net margin | 25.6% | 23.3% | 8.7% | 18.0% | 10.7% | 21.9% | 0.6% | 10.2% | 13.8% | −100.4% | 15.4% | 17.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BMY's financial statements (latest annual report filed February 11, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BMY financial results
In fiscal year 2025 (ended December 31, 2025), Bristol Myers Squibb reported revenue of $48.2 billion, down 0.2% from the year before. It had net income of $7.1 billion, a net profit margin of 14.6%. Diluted earnings per share came to $6.15. Over five years revenue grew at an average rate of 2.5% a year.
See the BMY stock overview for the latest quote and news, or the BMY chart for price history and technical indicators.
BMY income statement FAQ
What is Bristol Myers Squibb's annual revenue?
Bristol Myers Squibb reported total revenue of $48.2 billion for fiscal year 2025, which ended on December 31, 2025. That was down 0.2% from $48.3 billion the previous year.
Is Bristol Myers Squibb profitable?
Yes. Bristol Myers Squibb reported net income of $7.1 billion in fiscal 2025, a net profit margin of 14.6%; its operating margin was 28.5%.
What is Bristol Myers Squibb's gross margin?
Bristol Myers Squibb's gross margin was 71.1% in fiscal 2025: for every $100 of revenue, Bristol Myers Squibb kept $71 after the direct cost of its products and services.
How much does Bristol Myers Squibb spend on research and development?
Bristol Myers Squibb spent $10.0 billion on research and development in fiscal 2025, 20.6% of revenue.
How fast is Bristol Myers Squibb growing?
Revenue grew 2.5% a year on average over the last five fiscal years, from $42.5 billion to $48.2 billion.
What are Bristol Myers Squibb's earnings per share?
Bristol Myers Squibb earned $6.15 per diluted share in fiscal 2025, compared with $1.14 a year earlier.
When will Bristol Myers Squibb report its next earnings?
Bristol Myers Squibb is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens.
When does Bristol Myers Squibb's fiscal year end?
Bristol Myers Squibb's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 11, 2026.